Personnel

Gennevois named VP of medical affairs at cardiovascular device company

Published in Cardiovascular Week, October 6th, 2003

Corgentech, Inc., a privately-held biotechnology company, announced that Daniel Gennevois, MD, has been appointed vice president of medical affairs.

Gennevois has held a number of top clinical positions with leading biotechnology and pharmaceutical companies, including Roche Bioscience, Chiron Vaccines, and Syntex Corporation.

At Corgentech, Gennevois will oversee the company's pivotal phase III clinical trial studying its lead product, CGT003, an E2F Decoy therapy to prevent graft failure following coronary artery bypass graft (CABG) surgery. This trial is being conducted at approximately 100 leading medical centers in the United States and will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Week

Source: Cardiovascular Week (2003-10-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry